CD28 and acute myeloid leukemia: The first reported clinical trial that demonstrated clinical activity of CAR-T cell therapy in AML was with CD28-ζ CAR directed to Lewis Y antigen.386 Though there was disease progression with this therapy, this study demonstrated that CAR-T cell therapy could be safely administered in AML patients and has pushed forward the development of other CAR therapies.